SELB - Selecta Biosciences, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
13.81
-1.31 (-8.66%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close15.12
Open15.12
Bid13.00 x 3200
Ask14.50 x 800
Day's Range13.50 - 15.56
52 Week Range7.95 - 22.68
Volume184,120
Avg. Volume130,613
Market Cap309.292M
Beta (3Y Monthly)-3.47
PE Ratio (TTM)N/A
EPS (TTM)-3.09
Earnings DateNov 8, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.83
Trade prices are not sourced from all markets
  • American City Business Journals2 days ago

    Watertown biotech Selecta halts cancer drug trial after patient dies

    According to the company, one patient died after developing pneumonitis, while a second developed a potentially life-threatening buildup of fluid around the heart.

  • GlobeNewswire4 days ago

    Selecta Biosciences to Present New Five Monthly Dose Phase 2 Data for SEL-212 in Chronic, Severe Gout at Upcoming 2018 ACR Annual Meeting

    Selecta Biosciences, Inc. (SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that new data from the ongoing Phase 2 study of SEL-212 in chronic, severe gout will be presented at the upcoming 2018 American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) Annual Meeting, from October 19-23, 2018 in Chicago. “We continue to be impressed by the potential of SEL-212 to control uric acid levels and reduce the number of gout flares experienced by patients with chronic, severe gout,” said Werner Cautreels, Ph.D., president and CEO of Selecta.

  • Simply Wall St.19 days ago

    When Will Selecta Biosciences Inc (NASDAQ:SELB) Breakeven?

    Selecta Biosciences Inc’s (NASDAQ:SELB): Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company’s loss has recently Read More...

  • The Wall Street Journal23 days ago

    [$$] Selecta Biosciences Names President, CEO

    Selecta Biosciences Inc. (SELB) on Thursday said it named Carsten Brunn president and chief executive, effective Dec. 1. The Watertown, Mass., clinical-stage biopharmaceutical company said Mr. Brunn, 48 years old, succeeds Werner Cautreels, who is retiring.

  • GlobeNewswire23 days ago

    Selecta Biosciences Appoints Carsten Brunn, Ph.D. as President and Chief Executive Officer

    Selecta Biosciences, Inc. (SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, announced today that Carsten Brunn, Ph.D., has been appointed President and Chief Executive Officer (CEO) of Selecta Biosciences, effective December 1, 2018. Current President and CEO, Werner Cautreels, Ph.D., will continue to lead the company until December, will assist Dr. Brunn during the transition and will remain a member of the Board through December 31, 2018. Dr. Cautreels is expected to serve as an advisor to the company following his retirement.

  • GlobeNewswire25 days ago

    Selecta Biosciences to Present at the Cantor Fitzgerald Global Healthcare Conference on October 02, 2018

    Selecta Biosciences, Inc. (SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that CFO and Head of Corporate Strategy, John Leaman, M.D., will present at the Cantor Fitzgerald Global Healthcare Conference in New York City at 5:10 p.m. ET on Tuesday, October 02, 2018. A live and archived webcast of the presentation can be accessed via the Investors & Media section of the company’s website, http://selectabio.com. Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options.

  • GlobeNewswirelast month

    Selecta Biosciences to Present at the Jefferies Gene Therapy Summit on September 27, 2018

    Selecta Biosciences, Inc. (SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that CSO Takashi Kei Kishimoto, Ph.D., will present at the Jefferies Gene Therapy Summit in New York City at 9:10 a.m. ET on Thursday, September 27, 2018. A live webcast of the presentation can be accessed via the Investors & Media section of the company’s website, http://selectabio.com. Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options.

  • GlobeNewswirelast month

    Selecta Biosciences to Present at the Janney Healthcare Conference on September 17, 2018

    Selecta Biosciences, Inc. (SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that CFO and Head of Corporate Strategy John Leaman, M.D., will present at the Janney Healthcare Conference in New York City at 9:05 a.m. ET on Monday, September 17, 2018. A live webcast of the presentation can be accessed via the Investors & Media section of the company’s website, http://selectabio.com. Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options.

  • GlobeNewswire2 months ago

    Selecta Biosciences Announces Presentation at the 20th Asia Pacific League of Associations for Rheumatology Congress (APLAR)

    Selecta Biosciences, Inc. (SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that Chief Scientific Officer Takashi Kei Kishimoto, Ph.D. will present on the poster entitled Ongoing Phase 2 Clinical Trial of SEL-212 Shows Sustained Reduction of Serum Uric Acid by Mitigating Formation of Anti-Uricase Antibodies at the 20th Asia Pacific League of Associations for Rheumatology Congress (APLAR), taking place 6-9 September 2018 at the Kaohsiung Exhibition Centre, Taiwan. Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of SELB earnings conference call or presentation 8-Aug-18 12:30pm GMT

    Q2 2018 Selecta Biosciences Inc Earnings Call

  • GlobeNewswire2 months ago

    Selecta Biosciences Announces Second Quarter 2018 Financial Results and Provides Corporate Update

    Expanded three-month Phase 2 data presented at EULAR 2018 continue to indicate that SEL-212 product profile may provide better and more sustained serum uric acid control, fewer flares and less frequent ...

  • ACCESSWIRE2 months ago

    Selecta Biosciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Selecta Biosciences, Inc. (NASDAQ: SELB ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30:00 AM Eastern ...

  • GlobeNewswire3 months ago

    Selecta Biosciences to Present at the Canaccord Growth Conference on August 9, 2018

    Selecta Biosciences, Inc. (SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that CFO and Head of Corporate Strategy John Leaman, M.D., will be present at the Canaccord Genuity 38th Annual Growth Conference in Boston, Mass. at 2 p.m. ET on Wednesday, August 09, 2018. Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. Selecta plans to combine its tolerogenic Synthetic Vaccine Particles (SVP™) to a range of biologics for rare and serious diseases that require new treatment options.

  • GlobeNewswire3 months ago

    Selecta Biosciences Announces Date of Second Quarter 2018 Financial Results Conference Call

    Selecta Biosciences, Inc. (SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses, today announced that it plans to issue its second quarter 2018 financial results before the open of the U.S. financial markets on Wednesday, August 08, 2018. Investors and the public can access a live and archived webcast of this call via the Investors & Media section of the company’s website, http://selectabio.com. Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses.

  • Benzinga4 months ago

    Janney: 4 Reasons Why Selecta Biosciences Is 'Significantly Undervalued'

    Selecta Biosciences Inc (NASDAQ: SELB ) shares plummeted in November 2017 from the $20 level and have yet to recover. The stock should not only recoup all of its losses, but trade at new all-time highs, ...

  • When Will Selecta Biosciences Inc (NASDAQ:SELB) Breakeven?
    Simply Wall St.4 months ago

    When Will Selecta Biosciences Inc (NASDAQ:SELB) Breakeven?

    Selecta Biosciences Inc’s (NASDAQ:SELB): Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The US$274.90M market-cap posted aRead More...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of SELB earnings conference call or presentation 9-May-18 12:30pm GMT

    Q1 2018 Selecta Biosciences Inc Earnings Call

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of SELB conference call or presentation 10-Apr-18 12:30pm GMT

    Selecta Biosciences, Inc. - Special Call